皮肌炎自身抗体在间质性肺病中的研究进展

doi:10.11958/20231512

天津医药 ›› 2024, Vol. 52 ›› Issue (7): 704-708.doi: 10.11958/20231512

• 专题研究·结缔组织病-间质性肺病/肺动脉高压（主编魏蔚） • 上一篇下一篇

皮肌炎自身抗体在间质性肺病中的研究进展

罗宴冉¹^,²(), 史晓飞²^,^∆(), 韩磊², 张贝², 文路遥¹^,²

1 河南科技大学临床医学院（邮编471003）
2 河南科技大学第一附属医院风湿免疫科

收稿日期:2023-09-29 修回日期:2023-10-13 出版日期:2024-07-15 发布日期:2024-07-11
通讯作者: ^∆E-mail：xiaofeis@haust.edu.cn
作者简介:罗宴冉（1996），男，硕士在读，主要从事风湿免疫疾病相关研究。E-mail：1553025645@qq.com
基金资助:
河南省医学科技攻关计划省部共建重点项目(SBGJ202002098)

Research progress of dermatomyositis-related autoantibodies in interstitial lung disease

LUO Yanran¹^,²(), SHI Xiaofei²^,^∆(), HAN Lei², ZHANG Bei², WEN Luyao¹^,²

1 School of Clinical Medicine, Henan University of Science and Technology, Luoyang 471003, China
2 Department of Rheumatology and Immunology, the First Affiliated Hospital of Henan University of Science and Technology

Received:2023-09-29 Revised:2023-10-13 Published:2024-07-15 Online:2024-07-11
Contact: ^∆E-mail：xiaofeis@haust.edu.cn

罗宴冉, 史晓飞, 韩磊, 张贝, 文路遥. 皮肌炎自身抗体在间质性肺病中的研究进展[J]. 天津医药, 2024, 52(7): 704-708.

LUO Yanran, SHI Xiaofei, HAN Lei, ZHANG Bei, WEN Luyao. Research progress of dermatomyositis-related autoantibodies in interstitial lung disease[J]. Tianjin Medical Journal, 2024, 52(7): 704-708.

摘要/Abstract

摘要：

肌炎抗体分为肌炎特异性自身抗体（MSA）和肌炎相关性自身抗体（MAA）。不同肌炎抗体在间质性肺病（ILD）中的作用机制、临床特点及预后等方面存在异质性。在MSA中，抗黑色素瘤分化相关基因5（MDA5）抗体和抗氨酰tRNA合成酶（ARS）抗体与ILD的发生高度相关。抗MDA5抗体阳性皮肌炎（DM）患者ILD的发生率高，进展迅速，预后较差。抗ARS抗体阳性DM患者ILD的病程缓慢，对治疗反应较好，但易复发。在MAA中，抗Ro52抗体通常与MSA抗体共存，临床表现与共存抗体关系密切。就肌炎自身抗体在ILD中的研究进展进行综述。

关键词: 皮肌炎, 间质性肺病, 自身抗体, 临床特点, 预后

Abstract:

Myositis antibodies are divided into myositis-specific autoantibodies (MSA) and myositis-associated autoantibodies (MAA). There are heterogeneity in the mechanism, clinical features and prognosis of interstitial lung disease (ILD) in the different myositis antibodies. In MSA, anti-melanoma differentiation-related gene 5 (MDA5) antibody and anti-aminoacyl synthetase (ARS) antibody are highly correlated with the occurrence of ILD. Patients with MDA5⁺DM-ILD usually have a rapidly progressive and poor prognosis. The progress of ILD in ARS⁺ DM patients was slow, and the response to treatment is good, but it is easy to relapse. In MAA, anti-Ro52 antibodies often coexist with MSA antibodies, and clinical manifestation is closely related to coexisting antibodies. This review has summarized roles of myositis antibodies in ILD.

Key words: dermatomyositis, interstitial lung disease, antoantibody, clinical features, prognosis

中图分类号:

R593.26

参考文献 38

[1]	DEWANE M E, WALDMAN R, LU J. Dermatomyositis:Clinical features and pathogenesis[J]. J Am Acad Dermatol, 2020, 82(2):267-281. doi:10.1016/j.jaad.2019.06.1309.
[2]	WEN L, CHEN X, CHENG Q, et al. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies:results from a cohort from China[J]. Clin Rheumatol, 2022, 41(11):3419-3427. doi:10.1007/s10067-022-06291-z.
[3]	LIU Y, FENG S, LIU X, et al. IFN-beta and EIF2AK2 are potential biomarkers for interstitial lung disease in anti-MDA5 positive dermatomyositis[J]. Rheumatology(Oxford), 2023:kead117. doi:10.1093/rheumatology/kead117.
[4]	BUENO M, CALYECA J, ROJAS M, et al. Mitochondria dysfunction and metabolic reprogramming as drivers of idiopathic pulmonary fibrosis[J]. Redox Biol, 2020,33:101509. doi:10.1016/j.redox.2020.101509.
[5]	PHAN T H G, PALIOGIANNIS P, NASRALLAH G K, et al. Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis[J]. Cell Mol Life Sci, 2021, 78(5):2031-2057. doi:10.1007/s00018-020-03693-7.
[6]	YE Y, CHEN Z, JIANG S, et al. Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5⁺ dermatomyositis with therapeutic implications[J]. Nat Commun, 2022, 13(1):6458. doi:10.1038/s41467-022-34145-4.
[7]	LIANG L, ZHANG Y M, SHEN Y W, et al. Aberrantly expressed galectin-9 is involved in the immunopathogenesis of Anti-MDA5-positive dermatomyositis-associated interstitial lung disease[J]. Front Cell Dev Biol, 2021,9:628128. doi:10.3389/fcell.2021.628128.
[8]	SHIM J A, JO Y, HWANG H, et al. Defects in aminoacyl-tRNA synthetase cause partial B and T cell immunodeficiency[J]. Cell Mol Life Sci, 2022, 79(2):87. doi:10.1007/s00018-021-04122-z.
[9]	SEKIGUCHI A, ENDO Y, YAMAZAKI S, et al. Plasma homocysteine levels are positively associated with interstitial lung disease in dermatomyositis patients with anti-aminoacyl-tRNA synthetase antibody[J]. J Dermatol, 2021, 48(1):34-41. doi:10.1111/1346-8138.15602.
[10]	LI M, ZHANG Y, ZHANG W, et al. Type 1 interferon signature in peripheral blood mononuclear cells and monocytes of idiopathic inflammatory myopathy patients with different myositis-specific autoantibodies[J]. Front Immunol, 2023,14:1169057. doi:10.3389/fimmu.2023.1169057.
[11]	CERIBELLI A, TONUTTI A, ISAILOVIC N, et al. Interstitial lung disease associated with inflammatory myositis:Autoantibodies,clinical phenotypes,and progressive fibrosis[J]. Front Med (Lausanne), 2023,10:1068402. doi:10.3389/fmed.2023.1068402.
[12]	ZAMPELI E, MAVROMMATI M, MOUTSOPOULOS H M, et al. Anti-Ro52 and/or anti-Ro60 immune reactivity:autoantibody and disease associations[J]. Clin Exp Rheumatol, 2020, 38 Suppl 126(4):134-141.
[13]	INUI N, SAKAI S, KITAGAWA M. Molecular pathogenesis of pulmonary fibrosis,with focus on pathways related to TGF-β and the ubiquitin-proteasome pathway[J]. Int J Mol Sci, 2021, 22(11):6107. doi:10.3390/ijms22116107.
[14]	DECKER P, MOULINET T, PONTILLE F, et al. An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management[J]. Autoimmun Rev, 2022, 21(3):103013. doi:10.1016/j.autrev.2021.103013.
[15]	GUI X, SHENYUN S, DING H, et al. Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease[J]. Rheumatology (Oxford), 2022, 61(11):4570-4578. doi:10.1093/rheumatology/keac090.
[16]	XU L, YOU H, WANG L, et al. Identification of three different phenotypes in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis patients:implications for prediction of rapidly progressive interstitial lung disease[J]. Arthritis Rheumatol, 2023, 75(4):609-619. doi:10.1002/art.42308.
[17]	MCPHERSON M, ECONOMIDOU S, LIAMPAS A, et al. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease:A systematic review[J]. Semin Arthritis Rheum, 2022,53:151959. doi:10.1016/j.semarthrit.2022.151959.
[18]	WU W, GUO L, FU Y, et al. Interstitial lung disease in anti-MDA5 positive dermatomyositis[J]. Clin Rev Allergy Immunol, 2021, 60(2):293-304. doi:10.1007/s12016-020-08822-5.
[19]	TEEL A, LU J, PARK J, et al. The role of myositis-specific autoantibodies and the management of interstitial lung disease in idiopathic inflammatory myopathies:a systematic review[J]. Semin Arthritis Rheum, 2022,57:152088. doi:10.1016/j.semarthrit.2022.152088.
[20]	GONO T, KUWANA M. Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis[J]. Expert Rev Clin Immunol, 2020, 16(1):79-89. doi:10.1080/1744666x.2019.1699059.
[21]	MARCO J L, COLLINS B F. Clinical manifestations and treatment of antisynthetase syndrome[J]. Best Pract Res Clin Rheumatol, 2020, 34(4):101503. doi:10.1016/j.berh.2020.101503.
[22]	ALBAYDA J, MECOLI C, CASCIOLA-ROSEN L, et al. A North American Cohort of anti-sae dermatomyositis:clinical phenotype,testing,and review of cases[J]. ACR Open Rheumatol, 2021, 3(5):287-294. doi:10.1002/acr2.11247.
[23]	WONG V T, SO H, LAM T T, et al. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies[J]. Acta Neurol Scand, 2021, 143(2):131-139. doi:10.1111/ane.13331.
[24]	TANBOON J, NISHINO I. Update on dermatomyositis[J]. Curr Opin Neurol, 2022, 35(5):611-621. doi:10.1097/WCO.0000000000001091.
[25]	SABBAGH S, PINAL-FERNANDEZ I, KISHI T, et al. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis[J]. Ann Rheum Dis, 2019, 78(7):988-995. doi:10.1136/annrheumdis-2018-215004.
[26]	XING X, LI A, LI C. Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis[J]. Respir Med, 2020,172:106134. doi:10.1016/j.rmed.2020.106134.
[27]	GE Y, SHU X, HE L, et al. Interstitial lung disease is a major characteristic of patients who test positive for anti-PM/Scl antibody[J]. Front Med(Lausanne), 2021,8:778211. doi:10.3389/fmed.2021.778211.
[28]	VOJINOVIC T, CAVAZZANA I, CERUTI P, et al. Predictive features and clinical presentation of interstitial lung disease in inflammatory myositis[J]. Clin Rev Allergy Immunol, 2021, 60(1):87-94. doi:10.1007/s12016-020-08814-5.
[29]	ROMERO-BUENO F, DIAZ DEL CAMPO P, TRALLERO-ARAGUÁS E, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease[J]. Semin Arthritis Rheum, 2020, 50(4):776-790. doi:10.1016/j.semarthrit.2020.03.007.
[30]	LI X, LIU Y, CHENG L, et al. Roles of biomarkers in anti-MDA5-positive dermatomyositis,associated interstitial lung disease,and rapidly progressive interstitial lung disease[J]. J Clin Lab Anal, 2022, 36(11):e24726. doi:10.1002/jcla.24726.
[31]	SO J, SO H, WONG V T, et al. Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis[J]. Rheumatology(Oxford), 2022, 61(11):4437-4444. doi:10.1093/rheumatology/keac094.
[32]	GUI X, LI W, YU Y, et al. Prediction model for the pretreatment evaluation of mortality risk in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with interstitial lung disease[J]. Front Immunol, 2022,13:978708. doi:10.3389/fimmu.2022.978708.
[33]	AGGARWAL R, CASSIDY E, FERTIG N, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients[J]. Ann Rheum Dis, 2014, 73(1):227-232. doi:10.1136/annrheumdis-2012-201800.
[34]	GAN Y Z, ZHANG L H, MA L, et al. Risk factors of interstitial lung diseases in clinically amyopathic dermatomyositis[J]. Chin Med J (Engl), 2020, 133(6):644-649. doi:10.1097/cm9.0000000000000691.
[35]	CHEN H, LIU H, LYU W, et al. An observational study of clinical recurrence in patients with interstitial lung disease related to the antisynthetase syndrome[J]. Clin Rheumatol, 2023, 42(3):711-720. doi:10.1007/s10067-022-06424-4.
[36]	HUANG H L, LIN W C, LIN P Y, et al. The significance of myositis autoantibodies in idiopathic inflammatory myopathy concomitant with interstitial lung disease[J]. Neurol Sci, 2021, 42(7):2855-2864. doi:10.1007/s10072-020-04911-7.
[37]	GONZÁLEZ-PÉREZ M I, MEJÍA-HURTADO J G, PÉREZ-ROMÁN D I, et al. Evolution of pulmonary function in a cohort of patients with interstitial lung disease and positive for antisynthetase antibodies[J]. J Rheumatol, 2020, 47(3):415-423. doi:10.3899/jrheum.181141.
[38]	TAKEI R, YAMANO Y, KATAOKA K, et al. Predictive factors for the recurrence of anti-aminoacyl-tRNA synthetase antibody-associated interstitial lung disease[J]. Respir Investig, 2020, 58(2):83-90. doi:10.1016/j.resinv.2019.10.004.

皮肌炎自身抗体在间质性肺病中的研究进展

Research progress of dermatomyositis-related autoantibodies in interstitial lung disease

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 38

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨敏, 潘艳莎, 张长玲, 陈红英, 郭渠莲, 刘文君. 儿童急性淋巴细胞白血病基线数据及早期治疗反应与预后的相关性[J]. 天津医药, 2024, 52(9): 954-958.
[2]	王新波, 罗冰清, 石玉宝, 张也, 席江伟. 结直肠癌组织LncRNA LINC00342和miR-203a-3p表达及与预后的关系[J]. 天津医药, 2024, 52(9): 971-976.
[3]	戴瑶, 方向, 黄康, 冯洁, 刘敏, 伍松柏. HAT疗法治疗脓毒症休克的临床疗效观察[J]. 天津医药, 2024, 52(8): 825-829.
[4]	张锡友, 郭一丹, 张春霞, 周晓玲, 贾萌, 石志华, 罗洋. 老年维持性血液透析患者高钾血症与不良预后事件相关性的临床研究[J]. 天津医药, 2024, 52(8): 840-844.
[5]	满祎, 许娅, 何先成, 宋少锋, 刘爱国. 三阴性乳腺癌EGFR、Ki-67、P53及CTC表达与预后的关系研究[J]. 天津医药, 2024, 52(8): 862-867.
[6]	历丽, 曹树明, 杨仲平, 胡若梅. 鱼胶原低聚肽对急诊复杂手外伤手术患者预后的影响[J]. 天津医药, 2024, 52(8): 868-871.
[7]	尹韦玉, 廖红丽, 刘媛. SS相关抗体在特发性炎症性肌病及其相关间质性肺炎中的临床意义[J]. 天津医药, 2024, 52(7): 695-700.
[8]	王慧, 潘晴, 王宙明, 张娜, 杨振文, 魏蔚. 混合性结缔组织病相关肺动脉高压临床特点分析[J]. 天津医药, 2024, 52(7): 701-703.
[9]	薛晶, 元小冬, 邢爱君, 王连辉, 马倩, 符永山, 张萍淑. 急性缺血性脑卒中患者睡眠-觉醒生物节律变化与预后的关系研究[J]. 天津医药, 2024, 52(6): 614-619.
[10]	叶朝阳, 马建中, 李后俊, 魏鲲鹏. 急性胰腺炎患者外周血TLR4、IL-1β、NLR水平与疾病进展和预后的关系[J]. 天津医药, 2024, 52(6): 648-652.
[11]	吕梦娜, 李建斌, 吴锐. 自身炎症性疾病患者合并COVID-19严重程度的早期预测指标探讨[J]. 天津医药, 2024, 52(5): 528-531.
[12]	吴纪昆, 徐榕笛, 许景涵, 王乐, 丛洪良. 6种常见模型评分对NSTEMI患者远期预后预测价值的验证和比较[J]. 天津医药, 2024, 52(5): 541-547.
[13]	王宁方, 赵崇山, 刘方, 赵鹏浩, 张东东, 蔡卓纹, 蔡芳芳. 多发性骨髓瘤患者淋巴细胞来源微泡的检测及其临床意义[J]. 天津医药, 2024, 52(4): 409-415.
[14]	张文超, 杨雪辉, 尹涛, 王睿健, 张盟盟. 自发性急性脑出血患者血浆sCD163/sTWEAK比值与预后的关系[J]. 天津医药, 2024, 52(3): 297-301.
[15]	丁波, 龚洁芹, 沈李奎. 急性缺血性脑卒中患者血清指标与病情和预后的关系[J]. 天津医药, 2024, 52(2): 172-176.